Valuation: Evotec SE

Market Cap 623M 713M 575M 528M 1B 68.59B 1.02B 6.86B 2.69B 33.52B 2.68B 2.62B 116B P/E 2026 *
-4.4x
P/E 2027 * -12.2x
Enterprise Value 672M 768M 620M 570M 1.08B 73.93B 1.1B 7.4B 2.9B 36.13B 2.89B 2.82B 125B EV / Sales 2026 *
1.11x
EV / Sales 2027 * 0.95x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-6.51%
1 week-28.33%
Current month-29.85%
1 month-28.21%
3 months-36.77%
6 months-44.58%
Current year-35.67%
1 week 3.18
Extreme 3.176
5.1
1 month 3.18
Extreme 3.176
5.23
Current year 3.18
Extreme 3.176
6.73
1 year 3.18
Extreme 3.176
7.84
3 years 3.18
Extreme 3.176
24.44
5 years 3.18
Extreme 3.176
45.83
10 years 3.18
Extreme 3.176
45.83
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 43 2022-06-21
Date Insider Type Main position Quantity % Market Cap.
Jun. 14Sell

Chief Technology Officer

-119,900 0.0674%
May. 19Fiscal year

Chief Technology Officer

12,462 0.0070%
May. 03Buy

Head of Human Resources

15,228 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
-6.51%-28.33%-51.99%-84.00% 763M
-0.17%+1.47%+3.16%+6.80% 50.35B
-0.29%-2.81%+387.81%+591.82% 39.32B
-0.49%+1.48%+31.16%-6.46% 34.69B
+1.53%+3.11%+15.41%+58.54% 34.08B
+1.68%-0.62%+3.30%+27.34% 26.63B
+1.13%-3.11% - - 16.49B
-1.29%-0.52%+69.24%+117.60% 15.31B
+0.43%+3.34%+14.96%+17.46% 13.8B
+2.45%+3.99%+18.20%-30.12% 12.87B
Average -0.15%-2.00%+54.58%+77.66% 24.43B
Weighted average by Cap. +0.37%+0.70%+81.49%+121.61%

Financials

2026 *2027 *
Net sales 607M 694M 560M 514M 975M 66.76B 991M 6.68B 2.62B 32.63B 2.61B 2.55B 112B 765M 874M 705M 648M 1.23B 84.14B 1.25B 8.42B 3.3B 41.13B 3.28B 3.21B 142B
Net income -142M -162M -131M -120M -228M -15.61B -232M -1.56B -613M -7.63B -609M -596M -26.3B -39.8M -45.52M -36.71M -33.75M -63.95M -4.38B -65.04M -438M -172M -2.14B -171M -167M -7.38B
Net Debt 48.55M 55.53M 44.79M 41.17M 78.01M 5.34B 79.34M 535M 210M 2.61B 209M 204M 9B 101M 115M 93.06M 85.54M 162M 11.1B 165M 1.11B 436M 5.43B 433M 424M 18.7B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Date Price Change Volume
26-07-15 €3.506 -6.51% 3,409,216
26-07-14 €3.750 -24.12% 6,991,976
26-07-13 €4.942 -0.08% 371,645
26-07-10 €4.946 -0.88% 342,438
26-07-09 €4.990 +2.00% 289,624
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.506EUR
Average target price
5.986EUR
Spread / Average Target
+70.73%

Quarterly revenue - Rate of surprise